Effect of sacubitril valsartan combined with carvedilol in the treatment of elderly patients with chronic heart failure and its influences on TGF-β1 and CTGF levels
Objective To investigate the effect of sacubitril valsartan combined with carvedilol in the treatment of elderly patients with chronic heart failure and its influences on the levels of transforming growth factor-β1(TGF-β1)and connective tissue growth factor(CTGF).Methods A total of 100 elderly patients with chronic heart failure who were treated in our hospital from July 2020 to August 2022 were selected and randomly divided into control group and observation group,with 50 cases in each group.The control group was treated with carvedilol,and the observation group was treated with sacubitril valsartan on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the levels of TGF-β1 and CTGF in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the left ventricular ejection fraction(LVEF),cardiac output(CO)of the observation group were higher than those of the control group,left ventricular end diastolic dimension(LVEDD)and interventricular septal thickness(IVST)were lower than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion Sacubitril valsartan combined with carvedilol in the treatment of elderly patients with chronic heart failure can not only comprehensively improve the clinical effect,regulate the levels of TGF-β1 and CTGF,but also promote the recovery of cardiac function,with high safety,which is worthy of promotion.
NETL
NSTL
万方数据
